“急闯”港股，丸美生物突围还是解困？

Core Viewpoint - Marubi Biotechnology is seeking a dual listing in Hong Kong to enhance its capital strength and international financing capabilities, amid concerns over its financial health and high dividend payouts [2][4]. Group 1: Financial Performance and Pressures - Marubi's financial report indicates significant cash flow pressure, with a net cash outflow of 391 million yuan in Q3 2025, leading to a notable decrease in cash and cash equivalents [6]. - The company has short-term borrowings of 573 million yuan and total short-term liabilities of approximately 977 million yuan [8]. - Despite revenue growth, net profit growth has slowed, with a mere 2.13% increase in net profit attributable to shareholders in the first three quarters of 2025, while non-operating profit dropped by 5.42% [16]. Group 2: Dividend Policy and Shareholder Concerns - Marubi's dividend payout ratio has surged from 37.77% in 2019 to 202.82% in 2023, with a staggering 235.87% payout ratio in 2024, raising concerns among investors about the sustainability of such high dividends amid financial pressures [11]. - The majority of dividends benefit the founding couple, who hold over 80% of the shares, leading to investor worries about the prioritization of dividends over business reinvestment [11]. Group 3: Market Position and Competition - The competitive landscape in the domestic beauty industry is intensifying, with rising online traffic costs contributing to Marubi's struggle to increase profitability despite revenue growth [2]. - The company's reliance on online sales channels, which accounted for 87.6% of revenue in the first three quarters of 2025, has made it vulnerable to platform rules and rising costs [18]. Group 4: Technological Transformation and R&D Investment - Marubi is transitioning towards a biotechnology-focused beauty company, with significant investments in research and development, particularly in recombinant collagen products [20]. - However, R&D spending has not kept pace with sales expenses, with only a slight increase in R&D costs compared to a substantial rise in marketing expenses, indicating a potential imbalance in investment strategy [22].